In France, the government reported on 29 April that around 15 children were in hospital in Paris with symptoms of Kawasaki disease, an observation which prompted the organization of national surveillance programme for recent cases of Kawasaki-like disease.On 1 May, the RCPCH published a preliminary case definition based on review of the characteristics of the cases identified in the UK, accompanied by some clinical guidance. Two weeks later, on 15 May, two further preliminary case definitions were published separately by the WHO and by the CDC, while the ECDC released a rapid risk assessment of the condition on behalf of the European Union. In the following weeks, further clinical guidance was released by other medical organizations, including the NIH, the American College of Rheumatology, and the American Academy of Pediatrics. On 4 May, the New York City Department of Health and Mental Hygiene issued an alert to identify children with the condition in New York City hospitals, where 15 such cases were already being treated. On 9 May, the governor of New York, Andrew Cuomo announced a collaboration with the CDC to help develop national criteria for identifying and responding to the newly identified childhood disease.By 12 May, some 230 suspected cases had been reported across the EU and EEA, and in the UK (in the following days, sources were reporting up to 100 in the UK, over 135 in France, 20 in the Netherlands, 10 in Switzerland and 10 in Germany).
An editorial commentary urged clinicians to have a high level of diagnostic suspicion and follow  WHO and CDC definitions to facilitate timely identification and treatment of cases.During July, suspected cases were being flagged and reported in Mumbai, in Delhi, Chennai, and elsewhere. In Pakistan, at least 24 children were said to have Kawasaki-like symptoms in Lahore, where 8 cases fulfilling WHO criteria were prospectively identified by 30 June. In Kazakhstan, 14 cases were confirmed by 20 August (among 2,357 children known to have been infected). Cases have been recorded in Israel, including one of a child who presented with severe central nervous system involvement and complement deficiency. In Turkey, four children with a Kawasaki-like disease probably associated with COVID-19 are reported to have been admitted to the childrens hospital of Hacettepe University in Ankara between 13 April and 11 July. In Algeria, a first case was recorded in June. In Egypt, on 10 July the authorities denied rumours of the existence of cases of Kawasaki-like disease in the country. In South Africa, the first 23 affected children were treated in Cape Town – the initial epicentre of the national COVID-19 epidemic – between 4 June and 24 July. In Ecuador, the Ministry of Health announced on 19 July the presence of 46 probable cases.